永太科技(002326.SZ)連續4個漲停 已收到吉利德關於相關抗病毒藥物高級中間體的業務詢盤
格隆匯2月6日丨永太科技(002326.SZ)公佈,公司股票交易價格連續三個交易日(2020年2月4日、2020年2月5日和2020年2月6日)收盤價格漲幅偏離值累計超過20%,根據《深圳證券交易所股票上市規則》的有關規定,屬於股票交易異常波動情況。
公司正積極進行可行性研究工作,研究發現吉利德科學在研藥物Remdesivir(瑞德西韋)與公司現有產品鏈契合度高,和以往開發的同類產品有相似性,通過研發人員實驗室研究和中試化生產,可快速研發生產高級中間體片段。公司已收到吉利德關於相關抗病毒藥物高級中間體的業務詢盤,雙方正在洽談合作事宜,但此次是否能達成合作尚存在不確定性,且下遊客户在研藥物的臨牀試驗和藥品獲批存在不確定性且需要一定的時間。截至目前上述事項尚未對公司業績產生重大影響,未來可實現的業務規模尚存在不確定性,敬請廣大投資者注意投資風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.